biostudies-literatureZhang LNIMHAmerican College of Clinical PharmacyNCATS NIH HHSNIMH NIH HHS110464https://www.ebi.ac.uk/biostudies/studies/S-EPMC8932335biostudies-literatureUnknown113<h4>Background</h4>Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not been established.<h4>Methods</h4>Neuropsychological performance using the Brief Assessment of Cognition in Schizophrenia (BACS) was assessed in 616 individuals of European ancestry (403 psychosis, 213 controls). Polygenic risk scores for coronary artery disease (PRS_CAD) were quantified for each participant across 13 p-value thresholds (P_T 0.5-5e^-8). Cardiovascular and psychotropic medications were categorized for association analyses. Each PRS<suProgress in neuro-psychopharmacology & biological psychiatryImpact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.PMC8932335R01 MH078113MH-083126R01 MH077852R01 MH077851R01 MH077862MH-083888K08 MH083888UL1 TR001863K23 MH083126R01 MH103368K23 MH072767MH-072767MH-077945MH-078113R01 MH124813R01 MH077945MH-077852MH-077862MH-077851R01 MH103366Pearlson GDClementz BAHill SKKeshavan MSIvleva EIKeedy SKWu BZhang LKeefe RSEAlliey-Rodriguez NTamminga CAGershon ESEum SLizano PReilly JLGuo BSweeney JABishop JRfalseImpact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.<h4>Background</h4>Cognitive impairment is a core deficit across psychotic disorders, the causes and therapeutics of which remain unclear. Epidemiological observations have suggested associations between cognitive dysfunction in psychotic disorders and cardiovascular risk factors, but an underlying etiology has not been established.<h4>Methods</h4>Neuropsychological performance using the Brief Assessment of Cognition in Schizophrenia (BACS) was assessed in 616 individuals of European ancestry (403 psychosis, 213 controls). Polygenic risk scores for coronary artery disease (PRS_CAD) were quantified for each participant across 13 p-value thresholds (P_T 0.5-5e^-8). Cardiovascular and psychotropic medications were categorized for association analyses. Each PRS<su2022-01-01T00:00:00Z2022 Mar2025-04-19T13:30:51.845Z2025-04-19T13:30:51.845ZS-EPMC89323353475693210.1016/j.pnpbp.2021.110464